TY - JOUR
T1 - NCCN Guidelines Updates
T2 - Management of Patients With HER2-Negative Breast Cancer
AU - Gradishar, William J.
N1 - Publisher Copyright:
© 2022 Harborside Press. All rights reserved.
PY - 2022/6
Y1 - 2022/6
N2 - Treatment for metastatic HER2-negative breast cancer is becoming increasingly individualized as more of the tumor landscape is described and drugs are developed to target its pathways. Survival can be prolonged by CDK4/6 inhibitors in patients with hormone receptor-positive tumors and by immunotherapy in those with triple-negative disease. In patients with BRCA1/2 mutations, PARP inhibitors delay disease progression. Antibody-drug conjugates are expected to become critical components of the treatment landscape, and targeted drugs are proving to benefit small subsets of patients.
AB - Treatment for metastatic HER2-negative breast cancer is becoming increasingly individualized as more of the tumor landscape is described and drugs are developed to target its pathways. Survival can be prolonged by CDK4/6 inhibitors in patients with hormone receptor-positive tumors and by immunotherapy in those with triple-negative disease. In patients with BRCA1/2 mutations, PARP inhibitors delay disease progression. Antibody-drug conjugates are expected to become critical components of the treatment landscape, and targeted drugs are proving to benefit small subsets of patients.
UR - http://www.scopus.com/inward/record.url?scp=85131951417&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85131951417&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2022.5016
DO - 10.6004/jnccn.2022.5016
M3 - Article
AN - SCOPUS:85131951417
SN - 1540-1405
VL - 20
SP - 561
EP - 565
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
IS - 55
ER -
